Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

BMS 777607

Known as: BMS-777607, BMS777607, MET Tyrosine Kinase Inhibitor BMS-777607 
An inhibitor of MET tyrosine kinase with potential antineoplastic activity. MET tyrosine kinase inhibitor BMS-777607 binds to c-Met protein, or… 
National Institutes of Health

Related topics

Related topics

1 relation
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Pan-TAM Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti-PD-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer.
Tyro3, Axl, and Mertk (TAM) represent a family of homologous tyrosine kinase receptors known for their functional role in… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2019
Review
2019
Therapeutic Inducers of Apoptosis in Ovarian Cancer
Ovarian cancers remain one of the most common causes of gynecologic cancer-related death in women worldwide. The standard… 
  • figure 1
  • figure 2
  • table 1
  • table 1
  • figure 3
2016
2016
Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo
Purpose Receptor tyrosine kinase AXL (RTK-AXL) is regarded as suitable target in glioma therapy. Here we evaluate the anti… 
2014
2014
Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
  • figure 2
  • figure 3
  • figure 4
2013
2013
Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents
The RON receptor tyrosine kinase is a therapeutic target for cancer treatment. Here, we report therapeutic effect and phenotypic… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2013
2013
Synergistic Activities of MET/RON Inhibitor BMS-777607 and mTOR Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells
Tyrosine kinase inhibitor BMS-777067 is an inhibitor of RON/MET receptor tyrosine kinases currently under clinical trials. Here… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2013
2013
Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation.
2013
2013
Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors.
BACKGROUND We evaluated the mutation status of c-Met in small cell lung cancer (SCLC) and neuroendocrine tumors (NET), for which… 
Highly Cited
2010
Highly Cited
2010
BMS-777607, a Small-Molecule Met Kinase Inhibitor, Suppresses Hepatocyte Growth Factor–Stimulated Prostate Cancer Metastatic Phenotype In vitro
Most prostate cancer–related deaths are due to advanced disease with patients with metastatic prostate cancer having a 5-year… 
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Highly Cited
2009
Highly Cited
2009
Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of…
Substituted N-(4-(2-aminopyridin-4-yloxy)-3-fluoro-phenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamides were… 
  • table 1
  • figure 3
  • figure 1
  • table 3
  • table 2
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE